Drugs in sport: health implications, ethics and testing

Multiple choice: 1 → B. 2 → C. 3 → A. 4 → D. 5 → A.

Activity 1, indicative answers: 1 → Health: prolonged anti-inflammatory use carries gastrointestinal and kidney risks, but the dominant harm here is masking — a chronically sore knee that is medicated before every match for two months is a tissue being loaded while its warning signal is suppressed, and the underlying cause has never been assessed. Ethics: primarily a duty-of-care question for the adults around the athlete rather than a fairness one, with age relevant because a 17-year-old may not weigh the long-term cost against selection. Rule broken: generally none, which is exactly why this case matters — the most likely real harm in school sport involves no prohibited substance at all. The correct action is assessment and a change to load, as in Lessons 20 and 21. 2 → Health: raised red cell concentration thickens the blood, increasing the risk of clotting, stroke and heart attack, and the risk is greatest when the athlete is dehydrated at the end of a long event. Ethics: fairness, since the advantage is concealed and unavailable to competitors; safety; and coercion, because if it works undetected other athletes must match it. Rule broken: yes — many substances are prohibited at all times precisely because taking them in training and clearing them before competition would otherwise work, which is why out-of-competition testing exists. 3 → Health: unknown, since the athlete did not know what they were taking, which is itself part of the harm. Ethics: the athlete did not intend to cheat, so blame is different in kind, but competitors were still affected by the result. Rule broken: yes, under strict liability, because the athlete is responsible for what is in their sample regardless of intent — intent is unprovable, so a rule requiring it would be unenforceable. This is the Lesson 16 contamination risk realised, and the only real mitigation was using batch-tested products and refusing anything with an incomplete ingredient list. 4 → Health: the condition is being treated, and untreated illness carries its own risks. Ethics: none arise if the exemption process is properly documented and approved in advance. Rule broken: no. The case exists because athletes get ill and injured like everyone else, and a system with no medical exception would force them to choose between treatment and competing.

Activity 2, indicative answers: 1 → True part: sport genuinely is unequal in coaching, facilities, altitude access, equipment and money, so "fairness" is a line drawn rather than a natural boundary. What is wrong: it does not follow that no line should be drawn. The line is drawn where an advantage is both concealed and harmful, and the other inequalities are at least visible and do not require athletes to damage themselves. Reply: the objection to doping is not inequality as such. 2 → True part: autonomy matters, and adults do accept risks in sport routinely. What is wrong: the choice is not made in isolation. If doping works and goes undetected, other athletes face a choice between using it and being uncompetitive, which is coercion rather than free choice. Reply: an argument from individual autonomy answers a question about one athlete, and the difficulty is about everyone else. 3 → True part: all three claims are accurate — detection lags development, micro-dosing can fall below thresholds, and coverage below elite level is thin. What is wrong: the conclusion. An imperfect deterrent is not a useless one, and without it the coercion chain operates immediately. Reply: this is an argument for education, culture and better coverage alongside testing, not for abandoning it. 4 → True part: they were never found positive. What is wrong: a negative test means only that nothing was found on that day by that test, which is not the same as absence of use — particularly given the first three limitations. Reply: absence of evidence here is weak evidence of absence, and this is the single most commonly misstated point in the topic. The hardest to answer is the second, because autonomy is a genuine value rather than a bad argument, and the reply does not deny it — it points out that the coercion of others is a separate harm the autonomy claim does not address. At age 15 everything shifts: the developmental health risks are additional and some are irreversible, consent given because selection depends on it is not freely given, the athlete has less information and less power, and the adults around them carry the duty of care described in Lesson 9.

SA 1 (4 marks): What is used and why [1]: analgesics, anti-inflammatory drugs, corticosteroid injections and local anaesthetic are used to reduce pain and inflammation so an athlete can sleep, complete rehabilitation, or continue to participate. The masking mechanism [2]: pain is information, signalling that a tissue is not tolerating the load placed on it [1], so removing the signal while continuing to load the tissue allows an athlete to keep damaging themselves, converting a minor injury into a serious one, and this occurs with legal, often prescribed medication [1]. Other health effects [1], any one: gastrointestinal and kidney effects with prolonged anti-inflammatory use, or tissue weakening with repeated corticosteroid injection. The distinction [1, may be credited within the above]: appropriate use supports recovery — pain controlled so the athlete can sleep or perform rehabilitation exercises — while harmful use permits continued damage. It is a decision about purpose rather than a property of the substance.

SA 2 (6 marks): The system [3], any three features with a reason: a published prohibited list, updated annually, with some substances banned at all times and others only in competition, so athletes can know what is prohibited [1]; in-competition and out-of-competition testing including no-notice testing, because many substances are taken in training to build an advantage and cleared before competition [1]; whereabouts requirements, since notice defeats the purpose of testing and unpredictability is the mechanism [1]; A and B samples, protecting the athlete against laboratory error; strict liability, because intent is unprovable so a rule requiring proof of it would be unenforceable; therapeutic use exemptions, because athletes get ill and injured and a system with no medical exception would force a choice between treatment and competing; and sanctions with education. Three limitations [3]: detection lags development, so a new substance is undetectable until a test exists for it [1]; small repeated doses can fall below detection thresholds while still producing an effect [1]; testing is expensive so coverage below elite level is thin, and most athletes are effectively never tested [1]. A further creditable limitation is that a negative result means only that nothing was found on that day by that test, which is not proof that an athlete has not used a prohibited substance.

SA 3 (7 marks): Both halves identified [1]: the dot point covers drugs used in injury management, which are mostly legal and affect athletes at every level, and drugs used to enhance performance, which are prohibited and concentrated at higher levels — and answers that treat the topic as being only about doping miss the half that affects more athletes. Health implications with mechanisms [2]: for injury management, the dominant harm is masking, since pain signals that tissue is not tolerating load and suppressing it while continuing to load converts minor injuries into serious ones [1]; for performance enhancement, anabolic agents carry cardiovascular, liver and hormonal effects with additional developmental risks in adolescents, stimulants raise heart rate and blood pressure and impair temperature regulation, and agents raising red cell production thicken the blood and raise the risk of clotting, stroke and heart attack — and several of these risks are worst during exercise itself, which is exactly when the athlete takes them [1]. Ethical considerations [2]: fairness of competition, because a concealed advantage changes what a result means [1]; athlete safety, and age, since developmental risks are additional and a young athlete's consent is not freely given when selection depends on it; and coercion, which is the strongest of these — if doping works and is undetected, athletes who would not otherwise use it must match it or be uncompetitive [1]. Testing [1]: the system rests on a published prohibited list, in-competition and out-of-competition testing, whereabouts requirements, A and B samples, strict liability and therapeutic use exemptions, but it lags new substances, can be evaded by micro-dosing, is expensive so coverage is thin, and a negative result only means nothing was found on that day. The counter-argument, answered [1]: the strongest objection is that adults may accept risks with their own bodies and that sport is already unequal. The answer is that the choice is not made in isolation — the coercion of other athletes is a separate harm that autonomy does not address — and that the line is drawn not at inequality as such but where an advantage is both concealed and harmful.